by Justin Jackson , Medical Xpress Credit: Pixabay/CC0 Public Domain A multi-institute collaboration of 26 researchers led by the Mayo Clinic has developed a new asthma burden score that predicts disease severity and remission more accurately than current guidelines. ADVERTISING Asthma presents a significant health and economic challenge globally, with severity ranging from mild to...
Tag: <span>Asthma</span>
Post
Exclusive-US FDA Finds Widely Used Asthma Drug Impacts the Brain
Dan Levine And Sheila Dang November 22, 2024 Added to Email Alert 338 (Reuters) – U.S. government researchers have found that a widely prescribed asthma drug originally sold by Merck & Co may be linked to serious mental health problems for some patients, according to a scientific presentation reviewed by Reuters. The researchers found that...
Post
Diabetes meds metformin and GLP-1s can also curb asthma, research finds
by Ernie Mundell Drugs already taken by millions of diabetes patients appear to also help slash asthma attacks by up to 70%, new British research shows. The two drugs are metformin, one of the most widely used diabetes medications, and the GLP-1 class of medications that includes Ozempic, Mounjaro, and Saxenda. A study of nearly 13,000...
Post
How asthma could relate to kids’ memory function
Asthma is incredibly common among American youths, affecting about five million kids. Research published yesterday in JAMA Network Open found that the condition could have an effect on the development of some children’s episodic memory. In a longitudinal study of 475 kids ages 9-11, those with asthma scored lower on memory tests (in which they are asked...
Post
‘Gift That Keeps Giving’: The Impact of GLP-1 in Asthma
Akshay B. Jain, MD: Welcome back to Medscape at ADA 2024, where Dr James Kim, primary care physician from Calgary, Alberta, will be joining me, Akshay Jain, an endocrinologist from Vancouver, Canada, in deciphering the key highlights at the ADA conference and bringing our own clinical twist into what the relevance would be for people like...
Post
Monoclonal antibodies have the potential to treat severe asthma bouts, scientists find
University of Sharjah image: Caption: Airway remodeling in asthma refers to the structural changes that happen in airway passage to the lungs, increased muscle mass and gland enlargement. Credit: Clinical and Experimental Allergy (2024). DOI: org/10.1111/cea.14489 Scientists from the University of Sharjah think monoclonal antibodies hold the potential to be a far better treatment for...
Post
September is peak asthma month, allergist warns
July 29, 2024 by Dennis Thompson Peak asthma month is upon parents as summer draws to a close, experts warn. “September is known as Asthma Peak Month because kids have returned to school, and viruses are being passed around,” said allergist Dr. Gailen Marshall, president of the American College of Allergy, Asthma and Immunology. “September...
Post
Study elucidates crucial role of G900 gene enhancers in asthma-associated inflammation
JUNE 24, 2024 by Chiba University Researchers identify G900-dependent mechanism of in vivo Th2 differentiation. Credit: Arifumi Iwata from Chiba UniversityAsthma patients experience respiratory distress due to allergens like house dust mites or pollen. However, the various triggers for asthma share a common pathway involving the release of proteins called type-2 cytokines by Type-2 helper...
Post
What Are Platanus Cough and Thunderstorm Asthma? – diagnostic
Because of climate change, heat waves, storms, heavy rainfalls, and floods are now occurring in areas that seldom experienced these phenomena before. “Extreme weather events are rare, but in terms of their extent, duration, and scale, they are unusual. And they are increasing due to climate change,” said Andrea Elmer, MD, an internal medicine and...
Post
Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
Nathan L. Boyer, MD – Uniformed Services University of the Health Sciences DISCLOSURES March 04, 2022 The U.S. Food and Drug Administration (FDA) has approved the first-in-class biologic tezepelumab-ekko as an add-on maintenance treatment to standard therapy for severe asthma in adults and children aged 12 years and older. The approval is based on results...